A Phase 1 Open Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ASP0367 in Participants With Renal Impairment Compared to Healthy Participants With Normal Renal Function
Latest Information Update: 28 Nov 2023
At a glance
- Drugs Bocidelpar (Primary)
- Indications Chronic fatigue syndrome; Duchenne muscular dystrophy; Hypoxia; Metabolic disorders; Mitochondrial myopathies
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 20 Feb 2023 Status changed from recruiting to completed.
- 29 Dec 2021 Status changed from not yet recruiting to recruiting.
- 12 Nov 2021 New trial record